News & Analysis on Clinical Trial Services & Contract Research And Development
DCAT WEEK '17
Siegfried: Critical size key
By Melissa Fassbender
- Last updated on
For the last five years, Siegfried has been implementing its “transform” strategy.
In the last year, the company completed construction of a new API plant in Zofingen and initiated large-scale operations in China, said Rudolf Hanko, PhD, CEO at Siegfried.
“In a nutshell, what we wanted to achieve was grow as an integrated supplier, secondly, integrate horizontally, and most importantly, gain critical size,” said Hanko. “Critical size is absolutely key for success.”
Next, Hanko said Siegfied will further enhance its pure-play CDMO business model in addition to investing more in Micronization and other technologies to help “close the gaps.”